NHS England Emergency Preparedness, Resilience and Response annual assurance guidance – NHS England

This guidance document has been produced to provide guidance to organisations completing the Emergency Preparedness, Resilience and Response (EPRR) annual assurance process.  

Recommendations on the treatment and prophylaxis of tetanus – Public Health England

In April 2018, updated interim guidance was issued in response to changes in available IV immunoglobulin products in the NHS. Based on testing carried out by NIBSC of 7 other IV immunoglobulin products to determine if they have similar levels

The national childhood flu immunisation programme 2018 to 2019: information for healthcare practitioners – Public Health England

This document on the flu vaccination and vaccination programme includes information on: what flu is the flu vaccine dosage administering the vaccine advice on vaccinating children with an egg allergy further resources

Heatwave plan for England: Protecting health and reducing harm from severe heat and heatwaves – Public Health England

Updated Heatwave Plan for England which aims to prepare for, alert people to, and prevent, the major avoidable effects on health during periods of severe heat in England. It recommends a series of steps to reduce the risks to health

Evaluation Of The Implementation Of The Saving Babies’ Lives Care Bundle In Early Adopter NHS Trusts In England – University of Manchester

University of Manchester evaluation of the Saving Babies Lives Care Bundle that demonstartes clinical improvements such as better monitoring of a baby’s growth and movement in pregnancy, as well as better monitoring in labour, led to maternity staff helping to

Immunoglobulin Handbook – Public Health England

This handbook contains information, indications and guidance for the use of immunoglobulin preparations for each individual disease. Immunoglobulins are concentrated antibody preparations which provide immediate short-term protection against disease for individuals at high risk of severe disease or serious complications from

Musculoskeletal core capabilities framework for first point of contact practitioners – Arthritis and Musculoskeletal Alliance

Framework that sets out the essential skills and knowledge necessary for staff with a role as a first point of contact for adults presenting with undiagnosed musculoskeletal conditions. It is relevant to different types of service provision and settings, and

Heatwaves: adapting to climate change: Ninth Report of Session 2017–19: Report, together with formal minutes relating to the report – House of Commons Environmental Audit Committee

The average number of heat-related deaths in the UK is expected to more than triple to 7,000 a year by the 2050s. Older people are particularly vulnerable and suffer increased fatalities from cardiac and respiratory disease during heatwaves. As the

Ocrelizumab for treating relapsing–remitting multiple sclerosis: Technology appraisal guidance [TA533] – NICE

Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis in adults. Ocrelizumab is recommended as an option for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features, only if: alemtuzumab is contraindicated or

Transaxial interbody lumbosacral fusion for severe chronic low back pain: Interventional procedures guidance [IPG620] – NICE

Evidence-based recommendations on transaxial interbody lumbosacral fusion for low back pain in adults. This involves removing a damaged disc through a small cut at the base of the spine, and replacing it with an artificial implant. This guidance replaces NICE interventional

Superior capsular augmentation for massive rotator cuff tears: Interventional procedures guidance [IPG619] – NICE

Evidence-based recommendations on superior capsular augmentation for massive rotator cuff tears in adults. This involves using a graft to stabilise the shoulder joint, reduce pain and improve shoulder function.

Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer: Technology appraisal guidance [TA531] – NICE

Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer in adults. This guidance replaces NICE technology appraisal guidance 447.

Early and locally advanced breast cancer: diagnosis and management: NICE guideline [NG101] – NICE

This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person’s individual preferences. NICE has also produced guidelines on advanced breast cancer, familial breast

Medicines management for people receiving social care in the community: Quality standard [QS171] – NICE

This quality standard covers assessing if people need help with their medicines and deciding what medicines support is needed to enable people to manage their medicines. It also includes communication between health and social care staff, to ensure people have

Creutzfeldt-Jakob disease: guidelines for social workers in England – Department of Health and Social Care

These guidelines aim to increase awareness and understanding of CJD and improve social care for people who are affected by it. The guidelines update the previous guidance published in 2003. They reflect the increasing rareness of the disease and the

Ask Listen Do: Top tips for families and carers – NHS England

This booklet is designed to help families, parents and carers of those with a learning disability and autistic people to give feedback, raise concerns and make complaints across education, health and social care.

The variation between sub-optimal and optimal pathways: Rob’s story: Sepsis identification and care – NHS RightCare

In this scenario – using a fictional patient, Rob –  a sepsis care pathway is examined, comparing a sub-optimal but typical scenario against an ideal pathway. At each stage we have modelled the costs of care, not only financial to the local health

Prototype agreement scheme statement of financial entitlements – Departent of Health and Social Care

This document explains how remuneration is calculated, depending on how dental practices have entered a prototype agreement. The directions 2016 contain amendments to the statement of financial entitlement to make provision for the community dental services prototypes.

National Health Service Act 2006: The National Health Service (Dental Services) (Prototype Agreements) (Amendment) Directions 2018 – Department of Health And Social Care

Extending the dental prototype agreement scheme from 1 April 2018 to 31 March 2020.  Regulations setting out specific terms and conditions for dental prototype agreements.